The Pharmacologic Treatment of Schizophrenia: A Progress Report | Zendy

S. R. Donaldson | Zendy; Alan J. Gelenberg | Zendy; Ross J. Baldessarini | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Pharmacologic Treatment of Schizophrenia: A Progress Report

Author(s) -

S. R. Donaldson,

Alan J. Gelenberg,

Ross J. Baldessarini

Publication year - 1983

Publication title -

schizophrenia bulletin

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.823

H-Index - 190

eISSN - 1745-1707

pISSN - 0586-7614

DOI - 10.1093/schbul/9.4.504

Subject(s) - psychosis , schizophrenia (object oriented programming) , antipsychotic , psychiatry , carbamazepine , medicine , lithium (medication) , antidepressant , clonidine , acute psychosis , psychology , depression (economics) , anxiety , epilepsy , anesthesia , economics , macroeconomics

Pharmacologic agents currently used or being studied for the treatment of schizophrenia are reviewed. Neuroleptic medications are still the mainstay of treatment, but recent studies suggest new approaches to dosage and to the treatment of acute psychosis. Lithium is beneficial in psychotic illnesses with acute onset and a remitting course, regardless of the acute psychotic symptoms. Antidepressant agents may ameliorate depression in psychotic patients, but do not improve psychotic symptoms or social withdrawal. Propranolol's reported antipsychotic action has not been confirmed by controlled studies, but the drug may have a role in treating organic psychoses. The benzodiazepines, clonidine, and carbamazepine all merit more investigation as possible treatments for psychosis. The implications of differential treatment response among schizophrenic patients are discussed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research